RE:RE:Some insightI think the issue with MedX is they have said that they are engaged in a number of large scale contracts in mutiple countries. This is the tough part as investors, these type of contracts move at a very slow pace but once you get the go ahead it is large recurring revenue base to MedX for years to come. The Netherlands is a perfect example.
MedX making a big announcement about melanoma month is really wasting bullets as they have so few installs across Canada that it would be a waste of capital to announce the ease of this technology without having a place where people can go and be scanned. I am confident MedX will close some of these major contracts and then that will prove their strategy is correct.
An earlier poster commented about Dr. Champagne's qualifications being more administrative, this is factually incorrect.Here is his Bio from the Clevland Clinic;
https://my.clevelandclinic.org/canada/staff/champagne-trevor
Here are his areas of specialt interest;
Specialty Interests
- E-Health
- Teledermatology
- Artificial intelligence as applied to dermatology
He is the perfect Medical Advisory Chairman in my opinion.